61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Cara Therapeutics Inc
Open
Sector Healthcare
4.92 6.03
Overview
Share price change
24h
Min
4.62
Max
4.92
Sales | 991K |
|---|---|
EPS | -0.37 |
EBITDA | -15M |
Market Cap | -2.3M 46M |
|---|---|
Previous open | -1.11 |
Previous close | 4.92 |
News Sentiment
By Acuity
50%
50%
149 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Cara Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Cara Therapeutics Inc Forecast
Sentiment
By Acuity
149 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Cara Therapeutics Inc
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.
